Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Scientists solve the mystery of the prehistoric 'Burtele Foot' - 2The Most Vital Crossroads in Olympic History
- 3China’s new condom tax will prove no effective barrier to country’s declining fertility rate
- 4New science points to 4 distinct types of autism
- 5Find Successful Magnificence Items for Sparkling Skin
- Figure out How to Clean and Really focus on Your Lab Jewel
- 'The Real Housewives of Rhode Island' 1st teaser trailer unveiled: Which Bachelor Nation star is part of the cast? And when does it premiere?
- Volkswagen Just Built a Plug-In Tiguan for China That America Doesn’t Get
- Pentagon advances Golden Dome missile defense with new Space Force contracts
- Inflammatory Merz remarks on migrants' violence against women slammed
- Several Israelis attempt to cross into Gaza, escorted back to Israel by IDF
- Truly amazing Palaces: Which Is Your Number one?
- Avoid Large Crowds In Bali & Swim At This Peaceful Waterfall With A Gorgeous, Natural Pool
- Turkey’s intel chief lays out country’s vision for Middle East, world
